Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating mechanical ventilation strategies and the timing of muscle relaxation in patients with moderate to severe Acute Respiratory Distress Syndrome ARDS. The study aims to test personalized approaches for setting Positive End-Expiratory Pressure PEEP based on lung recruitability and whether early use of neuromuscular blocking agents NMBAs during prone positioning improves survival compared to rescue use. This trial addresses the lack of specific treatments for ARDS and focuses on improving survival by optimizing ventilation methods. Participants will be assigned to different ventilation strategies routine care with minimal lung distension using low tidal volume and conservative PEEP, routine care with maximal lung recruitment adjusting tidal volume and PEEP to maintain safe plateau pressures, or a personalized PEEP strategy based on a PEEP responsiveness test. Additionally, the study compares early systematic use of NMBAs during prone positioning to rescue use. Two randomizations occur first for ventilation strategy and second for NMBA timing. During the study, participants will undergo mechanical ventilation with assigned strategies, and researchers will monitor oxygenation, respiratory parameters, organ function scores, and mortality over time. Assessments include arterial blood gases, tidal volumes, respiratory rates, and organ failure evaluations at multiple time points up to one year. The primary outcome is 28-day all-cause mortality. Safety and long-term outcomes such as disability, cognitive function, quality of life, and return to work status will also be evaluated throughout the follow-up period.
Actively Recruiting
Researchers are studying patients with community-acquired pneumonia who need oxygen therapy due to acute respiratory distress and low blood oxygen levels. This research aims to see if placing patients in a prone position lying face down while they receive nasal high flow oxygen can reduce the need for intubation and improve outcomes. The study particularly excludes patients with COVID-19 and focuses on non-COVID pneumonia cases. Participants will be randomly assigned to one of two groups. One group will be encouraged and assisted to lie in the prone position for at least 8 hours per day in multiple sessions, aiming for up to 16 hours if tolerated. The other group will receive usual care with nasal high flow oxygen therapy but no prone positioning. Both groups will have oxygen levels monitored and care adjusted to maintain target oxygen saturation. During the study, patients will be observed for intubation rates within 28 days, comfort levels during prone positioning, oxygenation changes, time to escalation of breathing support, and overall outcomes including mortality up to 90 days. Safety measures like skin and infection monitoring will also be recorded. Quality of life will be assessed at 90 days and 5 years, with nursing workload tracked within the first day after randomization.
Actively Recruiting
Gout is a common inflammatory condition caused by high levels of uric acid leading to painful joint attacks and potentially chronic joint damage, kidney failure, and cardiovascular problems. This trial investigates whether starting febuxostat, a urate-lowering medication, immediately after an acute gout attack is as safe and effective as the current practice of delaying treatment by six weeks. The study aims to better understand if early treatment can prevent worsening of gout and its complications without increasing early relapses. Participants are randomly assigned to one of two groups one begins febuxostat treatment immediately at 80 mg daily for 12 weeks, and the other starts febuxostat only after a six-week delay. The study includes an initial 6-week comparison period, followed by an extension phase where all participants receive febuxostat, and a final evaluation at six months to assess ongoing treatment effects. Febuxostat is chosen for its potency and suitability for patients with moderate kidney issues. Throughout the study, participants will report daily gout symptoms and pain levels using a diary and visual scales. Physical and joint examinations, blood tests to monitor uric acid and inflammation, and assessments of physical function will occur at 2, 6, 12, and 26 weeks. Researchers will track the number of days with gout attacks, treatment tolerance, and overall patient well-being to compare early versus delayed febuxostat use. The study is conducted with blinded evaluators to ensure unbiased results.
Actively Recruiting
Researchers are evaluating whether a personalized rehabilitation program that combines nutrition, physiotherapy, and physical activity, started early in the intensive care unit ICU and continued through hospital discharge and at home, can improve long-term outcomes for patients who have undergone invasive mechanical ventilation and vasopressor therapy. This trial compares this early extended rehabilitation approach to usual care, which involves standard nutritional support and physiotherapy provided according to local ICU practices. Participants will be randomly assigned to either the individualized rehabilitation group or the usual care group. The rehabilitation group will receive a tailored program involving dieticians, physiotherapists, and physical activity instructors, with the intervention continuing for 12 weeks from ICU admission through post-ICU wards and at home. The usual care group will receive standard nutritional and physiotherapy support from day 0 to day 180. Throughout the study, participants will undergo various assessments including physical activity levels, muscle strength, muscle mass, body weight, and quality of life measured at multiple time points up to 12 months after randomization. The primary outcome is the distance walked in six minutes at 6 months. Researchers will also track mortality rates, glucose control, insulin usage, infection rates, and hospital stay lengths. The total participation may last up to 12 months with follow-up evaluations during this period.
Actively Recruiting
De novo hypoxemic acute respiratory failure hARF is a leading cause of admission to intensive care units ICU and is associated with a high risk of death when intubation is needed. Researchers are evaluating whether adding continuous positive airway pressure CPAP to high flow nasal cannula HFNC oxygen therapy can reduce mortality compared to HFNC alone. The trial is a prospective, randomized controlled study focused on patients with de novo acute hypoxemic respiratory failure. Participants will be randomly assigned to one of two groups. One group will receive continuous HFNC oxygen started within one hour after randomization. The other group will receive HFNC combined with CPAP sessions, which provide positive airway pressure to help keep lungs open without added breathing support. The study compares these two oxygenation strategies to see their impact on patient outcomes. During the study, patients will be closely monitored for 90 days to assess mortality and other outcomes such as time to intubation, breathing difficulty, respiratory rate, and tolerance of oxygen therapy. Additional measures include length of ICU and hospital stay, incidence of infections, and number of days free from invasive ventilation or HFNC. Various clinical assessments and blood tests may be performed as needed. The study aims to gather detailed information on safety and effectiveness of the combined CPAP plus HFNC approach over several months.
Actively Recruiting
Researchers are investigating the effects of different target mean arterial pressure MAP levels on neurofunctional outcomes in adults who have experienced out-of-hospital cardiac arrest. This condition often leads to death in intensive care units due to shock or brain damage caused by lack of oxygen. The study aims to compare a standard MAP target of at least 65 mmHg with a higher target of at least 90 mmHg during the first 24 hours after cardiac arrest, as current practices and studies suggest that brain blood flow regulation may require different pressure levels to improve recovery. Participants will be randomly assigned to one of two groups. One group will receive norepinephrine to maintain a high MAP of at least 90 mmHg for 24 hours, then switch to the standard target of 65 mmHg until ICU discharge. The other group will receive norepinephrine to maintain the standard MAP target of at least 65 mmHg for 24 hours, continuing this target until ICU discharge. This approach evaluates whether a higher blood pressure target soon after cardiac arrest improves neurological recovery. During the study, participants will be monitored in the ICU with ongoing assessments including survival status and neurofunctional outcomes up to 180 days after inclusion. Researchers will also observe secondary outcomes such as quality of life, clinical frailty, organ support needs, and kidney function. The study will track these measures through hospital discharge and several months afterward to assess the longer-term effects of the MAP targets on recovery and health.
Actively Recruiting
Obesity is a growing public health issue that can be difficult to treat through diet, exercise, and managing psychological challenges alone. Bariatric surgery is an option for patients with a body mass index BMI of 40 or higher, or 35 or higher with related health problems like type 2 diabetes or sleep apnea, when other treatments have failed. A common surgical challenge is the increased fat and size of the liver, which can complicate the procedure. This research evaluates the effects of a low-calorie, high-protein diet taken for four weeks before bariatric surgery. One group will follow this diet to reduce liver fat and size, while another group will not follow the diet. The diet aims to make surgery easier and safer by reducing fat load and improving surgical conditions. Participants will be monitored before and after surgery with assessments of diet tolerance, weight loss, muscle strength, quality of life, physical activity, digestive tolerance, and surgical outcomes such as operating time and complications. The study includes follow-ups up to three months after surgery and tracks hospital stay length and post-surgery complications, with the total observation lasting four months after surgery.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
This research aims to screen people who use drugs for hepatitis B, hepatitis C, and AIDS viruses. It focuses on identifying active infections using a simple blood collection method. The study is sponsored by the University Hospital, Rouen, and does not involve experimental drug treatments but diagnostic testing. Participants will have their blood collected using a Dried Blood Spot method, which is a minimally invasive way to collect samples. The study includes individuals who are former or current intravenous or nasal drug users, as well as those on opiate substitution therapy. The screening occurs at the start of participation to detect active infections. Participants will be assessed on the first day for active hepatitis B, hepatitis C, and AIDS infections. The main measurements are the number of individuals found to have active infections of these viruses. This study does not involve any treatment and focuses on diagnostic testing and data collection during the initial visit.
Actively Recruiting
Healthy Volunteer
Researchers are collecting detailed data on adults experiencing convulsive and non-convulsive status epilepticus SE or pseudo status epilepticus. This observational study aims to understand the circumstances, treatment, and outcomes of SE in critically ill patients by gathering extensive clinical and demographic information. The study is sponsored by the Ictal Group and tracks patient progress up to one year after SE onset. Participants with SE are observed without intervention, focusing on data collection such as seizure onset, treatment timing, EEG monitoring results, and seizure characteristics. The study includes both convulsive and non-convulsive SE cases, as well as pseudo SE, using standardized forms to document pre-hospital and hospital care details. Outcome evaluations are scheduled at ICU and hospital discharge, and follow-ups occur at 90 days and one year after SE. During the study, participants vital status and neurological outcomes are assessed using the Glasgow Outcome Scale at multiple timepoints. Researchers also monitor seizure recurrence, total seizure duration, and length of hospital stay. The study tracks mortality rates at ICU and hospital discharge and up to ten years in secondary measures. Data collection includes patient chart reviews and phone interviews to ensure comprehensive follow-up over time.
1-10 of 11
1